---
id: 086
title: Skin and Soft Tissue Infections Classification and Treatment
category: clinical_syndromes
subcategory: ssti
tags: [cellulitis, abscess, necrotizing-fasciitis, MRSA, purulent, non-purulent]
difficulty: medium
---

## Question

How are SSTIs classified and treated? Use the **"PURULENT vs NON-PURULENT vs NECROTIZING"** framework.

## Answer

### **SSTI Classification:**

**1. PURULENT (Abscess, Furuncle, Carbuncle):**
- **Primary pathogen:** *S. aureus* (often CA-MRSA)
- **Treatment:** **I&D (most important) ± antibiotics**
- **Antibiotics (if indicated):**
  - TMP-SMX DS BID or doxycycline 100mg BID × 5-10 days
  - Clindamycin 300-450mg TID (if D-test negative)

**2. NON-PURULENT (Cellulitis, Erysipelas):**
- **Primary pathogen:** β-hemolytic strep (*S. pyogenes*) > *S. aureus*
- **Treatment:** Antibiotics (no I&D)
- **Mild-Moderate:**
  - **Cephalexin** 500mg PO QID or **dicloxacillin** 500mg QID × 5-10 days
- **Severe/Failed:**
  - Add MRSA coverage (vancomycin, linezolid, or daptomycin)

**3. NECROTIZING (Necrotizing Fasciitis, Gas Gangrene):**
- **Pathogens:**
  - **Type I (polymicrobial):** Strep, anaerobes, Gram-negatives
  - **Type II (monomicrobial):** ***S. pyogenes*** (GAS), *C. perfringens*
- **Treatment:** **URGENT surgical debridement + broad-spectrum antibiotics**
- **Antibiotics:**
  - Vancomycin + pip-tazo (or meropenem) + **clindamycin**
  - **Clindamycin essential** (toxin suppression)

## Key Points

### **When to Add MRSA Coverage:**

**Purulent SSTIs:**
- **Always consider** (CA-MRSA most common cause of abscesses)
- I&D alone may suffice for small abscess
- Add antibiotics if: large abscess (>5cm), systemic signs, failed I&D alone, immunocompromised

**Non-Purulent Cellulitis:**
- **Add MRSA coverage if:**
  - Severe infection
  - Systemic toxicity
  - Failed β-lactam therapy
  - Known MRSA colonization/infection
  - Purulent drainage develops

### **Red Flags for Necrotizing Fasciitis:**

- **Pain out of proportion** to exam findings
- **Rapid progression** of erythema/swelling
- **Skin necrosis, bullae, crepitus**
- **Systemic toxicity** (fever, hypotension)
- **Elevated CK, high WBC**
- **LRINEC score ≥6** (Laboratory Risk Indicator for Necrotizing Fasciitis)

**LRINEC Score Components:**
- CRP, WBC, Hgb, Na, Cr, glucose
- **Score ≥6:** High risk for necrotizing fasciitis

### **Treatment Principles:**

**Purulent:**
1. **I&D is primary** therapy
2. Antibiotics if severe, systemic, or >5cm
3. Cover MRSA (TMP-SMX, doxy, clindamycin)

**Non-Purulent:**
1. **β-lactam** (cephalexin) first-line
2. Add MRSA coverage if severe/failed
3. No I&D (no abscess to drain)

**Necrotizing:**
1. **Urgent surgery** (debridement within 6 hours)
2. **Broad-spectrum antibiotics** (vanc + pip-tazo + clindamycin)
3. **Clindamycin** critical (toxin suppression)

### **Clinical Pearls:**
- **Purulent SSTI:** I&D ± MRSA antibiotics (TMP-SMX, doxy)
- **Non-purulent cellulitis:** β-lactam first-line (cephalexin)
- **Necrotizing fasciitis:** **URGENT surgery** + broad antibiotics + clindamycin
- **Pain out of proportion** = red flag for necrotizing infection
- I&D alone may suffice for **small abscesses** (<5cm)

## Sources

- [IDSA: SSTI Guidelines 2014]
- [Surgical Infections: Necrotizing Fasciitis]

## Media

N/A
